CompuGroup Medical SE & Co. KGaA

WBAG:COP2 Stock Report

Market Cap: €1.1b

CompuGroup Medical SE KGaA Valuation

Is COP2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COP2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€34.91
Fair Value
36.9% undervalued intrinsic discount
9
Number of Analysts

Below Fair Value: COP2 (€22.04) is trading below our estimate of fair value (€34.91)

Significantly Below Fair Value: COP2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COP2?

Key metric: As COP2 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COP2. This is calculated by dividing COP2's market cap by their current earnings.
What is COP2's PE Ratio?
PE Ratio45.2x
Earnings€25.17m
Market Cap€1.14b

Price to Earnings Ratio vs Peers

How does COP2's PE Ratio compare to its peers?

The above table shows the PE ratio for COP2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.2x
NXU Nexus
44x17.1%€1.2b
HSTM HealthStream
50.1x5.8%US$980.9m
EMIS EMIS Group
40.4x11.0%UK£1.2b
EQS Equasens Société anonyme
14.5x11.4%€611.0m
COP2 CompuGroup Medical SE KGaA
45.2x30.5%€1.1b

Price-To-Earnings vs Peers: COP2 is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the peer average (36.1x).

Price to Earnings Ratio vs Industry

How does COP2's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
COP2 45.2xIndustry Avg. 34.2xNo. of Companies3PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COP2 is expensive based on its Price-To-Earnings Ratio (45.2x) compared to the Global Healthcare Services industry average (34x).

Price to Earnings Ratio vs Fair Ratio

What is COP2's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COP2 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COP2's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COP2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€22.04
€21.56
-2.2%
26.3%€29.00€10.00n/a9
Jan ’26€21.80
€21.56
-1.1%
26.3%€29.00€10.00n/a9
Dec ’25€15.95
€21.75
+36.4%
25.6%€31.00€16.00n/a10
Nov ’25€13.78
€26.85
+94.8%
50.2%€64.00€16.00n/a10
Oct ’25€14.10
€27.25
+93.3%
48.5%€64.00€16.00n/a10
Sep ’25€15.56
€29.95
+92.5%
53.3%€64.00€16.00n/a10
Aug ’25€15.90
€29.95
+88.4%
53.3%€64.00€16.00n/a10
Jul ’25€23.80
€42.80
+79.8%
29.5%€64.00€31.00n/a10
Jun ’25€27.64
€43.20
+56.3%
30.4%€64.00€31.00n/a10
May ’25€28.14
€46.05
+63.6%
25.8%€65.00€32.50n/a10
Apr ’25€28.48
€48.45
+70.1%
22.1%€65.00€36.00n/a10
Mar ’25€29.02
€48.45
+67.0%
22.1%€65.00€36.00n/a10
Feb ’25€39.68
€54.05
+36.2%
22.1%€76.00€39.00n/a10
Jan ’25€37.90
€55.50
+46.4%
20.7%€76.00€41.00€21.8010
Dec ’24€35.16
€54.91
+56.2%
17.9%€70.00€41.00€15.9511
Nov ’24€34.78
€55.91
+60.8%
16.2%€70.00€41.00€13.7811
Oct ’24€37.14
€55.91
+50.5%
16.2%€70.00€41.00€14.1011
Sep ’24€43.30
€56.82
+31.2%
15.1%€70.00€41.00€15.5611
Aug ’24€46.20
€57.82
+25.1%
13.4%€70.00€41.00€15.9011
Jul ’24€44.88
€57.82
+28.8%
13.4%€70.00€41.00€23.8011
Jun ’24€50.00
€57.41
+14.8%
15.1%€70.00€36.50€27.6411
May ’24€49.90
€57.41
+15.0%
15.1%€70.00€36.50€28.1411
Apr ’24€47.50
€58.14
+22.4%
15.8%€70.00€36.50€28.4811
Mar ’24€44.90
€58.05
+29.3%
16.0%€70.00€36.50€29.0211
Feb ’24€44.56
€57.55
+29.1%
19.1%€68.00€36.50€39.6811
Jan ’24€36.14
€57.55
+59.2%
19.9%€68.00€36.50€37.9011
Analyst Price Target
Consensus Narrative from 9 Analysts
€21.59
Fair Value
2.1% overvalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 10:29
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CompuGroup Medical SE & Co. KGaA is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard SchwarzBaader Helvea Equity Research
Knut WollerBaader Helvea Equity Research
Gunnar CohrsBerenberg